In this study comparing BAT to Enza after Zytiga failure, the researchers found a response of approximately 28%. BAT demonstrated a clinically superior activity level compared with Enza. It also was associated with the same progression-free survival and numerically more prolonged PSA progression-free survival and overall survival.